European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics

Descrizione del progetto

Una rete di formazione europea per la ricerca traslazionale sul glioblastoma

Il glioblastoma (GBM) è un tumore cerebrale molto aggressivo e letale: l’85 % dei pazienti muore entro due anni dalla sua insorgenza. Non esiste attualmente una terapia efficace per il GBM e sono quindi urgentemente necessarie nuove opzioni terapeutiche. Il progetto GLIOTRAIN, finanziato dalle azioni Marie Skłodowska-Curie, si concentrerà sullo sviluppo di una rete di formazione europea per la ricerca composta da 14 organizzazioni di 8 Paesi, allo scopo di formare 15 giovani ricercatori creativi. L’obiettivo di GLIOTRAIN è scoprire nuove strategie terapeutiche per il trattamento del GBM, utilizzando il sequenziamento di nuova generazione, la medicina dei sistemi e la multi-omica integrativa per comprendere i meccanismi di resistenza della malattia. La rete del progetto preparerà una nuova generazione di scienziati per affrontare la ricerca traslazionale e la cura clinica del GBM.

Obiettivo

Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and effective precision medicine therapies are urgently required. This can only be achieved by focused multi-sectoral industry-academia collaborations in newly emerging, innovative research disciplines. GLIOTRAIN will exploit the intractability of GBM to address European applied biomedical research training needs. The ETN, which comprises 9 beneficiaries and 14 partner organisations from 8 countries, will train 15 innovative, creative and entrepreneurial ESRs. The research objective of GLIOTRAIN is to identify novel therapeutic strategies for application in GBM, while implementing state of the art next generation sequencing, systems medicine and integrative multi-omics to unravel disease resistance mechanisms. Research activities incorporate applied systems medicine, integrative multi-omics leveraging state of the art platform technologies, and translational cancer biology implementing the latest clinically relevant models. The consortium brings together leading European and international academics, clinicians, private sector and not-for-profit partners across GBM fields of tumour biology, multi-omics, drug development, clinical research, bioinformatics, computational modelling and systems biology. Thus, GLIOTRAIN will address currently unmet translational research and clinical needs in the GBM field by interrogating innovative therapeutic strategies and improving the mechanistic understanding of disease resistance. The GLIOTRAIN ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans translational research, medicine and computational biology, and that can navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.

Coordinatore

ROYAL COLLEGE OF SURGEONS IN IRELAND
Contribution nette de l'UE
€ 1 062 698,40
Indirizzo
ST STEPHEN'S GREEN 123
2 Dublin
Irlanda

Mostra sulla mappa

Regione
Ireland Northern and Western Border
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 1 062 698,40

Partecipanti (8)

Partner (14)